Chardan likes Kodiak Sciences in premarket analyst action

|About: OrthoPediatrics Corp. (KIDS)|By:, SA News Editor

OrthoPediatrics (NASDAQ:KIDS) initiated with Outperform rating and $44 (17% upside) price target at JMP Securities.

Homology Medicines (NASDAQ:FIXX) initiated with Buy rating and $36 (50% upside) price target at H.C. Wainwright.

Kodiak Sciences (NASDAQ:KOD) initiated with Buy rating and $22.50 (229% upside) price target at Chardan Capital Markets citing bullish prospects for lead drug KSI-301. Shares up 7% premarket.

Pfizer (NYSE:PFE) resumed with Neutral rating and $41 (4% downside risk) at Citigroup.

IRhythm (NASDAQ:IRTC) downgraded to Neutral with a $104 (13% upside) price target at Chardan citing valuation.

National Health Investors (NYSE:NHI) downgraded to Underperform with a $74 (8% downside risk) price target at BMO. Shares down 3% premarket.

Subscribe for full text news in your inbox